60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP – Get Free Report) was the target of a large increase in short interest in October. As of October 30th, there was short interest totaling 255,088 shares, an increase of 88.4% from the October 15th total of 135,408 shares. Based on an average daily trading volume, of 1,664,816 shares, the days-to-cover ratio is currently 0.2 days. Currently, 7.4% of the shares of the stock are short sold.
60 Degrees Pharmaceuticals Stock Down 0.2%
60 Degrees Pharmaceuticals stock traded down $0.00 during midday trading on Friday, reaching $0.52. 24,896 shares of the stock traded hands, compared to its average volume of 1,003,654. The stock’s fifty day moving average is $0.94 and its 200-day moving average is $1.65. 60 Degrees Pharmaceuticals has a 12 month low of $0.48 and a 12 month high of $8.62. The stock has a market cap of $1.82 million, a P/E ratio of -0.11 and a beta of 2.47.
60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.16). The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.20 million. On average, equities analysts predict that 60 Degrees Pharmaceuticals will post -3.31 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Monday, September 21st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $13.85.
Check Out Our Latest Research Report on 60 Degrees Pharmaceuticals
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments and preventive therapies for conditions that affect travelers, military personnel and populations in regions where infectious diseases are prevalent. Its lead product is Arakoda (tafenoquine), an oral prescription medicine approved by the U.S. Food and Drug Administration in 2018 for the prevention of malaria in adults.
Featured Stories
- Five stocks we like better than 60 Degrees Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
